Rochester, Minnesota
Cancer clinical trials in Rochester, MN
210 cancer studies are recruiting participants at sites in Rochester as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Rochester at a glance
- 210 studies are recruiting at a site in Rochester.
- By phase: Early Phase 1 (2), Phase 1 (29), Phase 1/2 (37), Phase 2 (35), Phase 2/3 (6), Phase 3 (51), Phase 4 (4), No phase (16), Observational (30). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (110), university, hospital or other (91), government (9).
- By research area: Breast Cancer (56), Lymphoma (50), Lung Cancer (48), Pancreatic Cancer (25), Prostate Cancer (21), Melanoma (10).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Rochester
Basic details from each study's public record (the 30 most recently updated of 210). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- LeonaBio
- Study site
- Mayo Clinic - Rochester
- Registry record
- NCT05696626 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT05564377 · updated
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Stemline Therapeutics, Inc.
- Study site
- Mayo Clinic
- Registry record
- NCT06638307 · updated
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- ALX Oncology Inc.
- Study site
- Mayo Clinic Cancer Center
- Registry record
- NCT07007559 · updated
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- ORIC Pharmaceuticals
- Study site
- Mayo Clinic
- Registry record
- NCT05315700 · updated
Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06953245 · updated
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study site
- Mayo Clinic Rochester
- Registry record
- NCT05633654 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT05879926 · updated
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors
- Phase 2
- Ages 18 and older
- Female participants
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06028022 · updated
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Wake Forest University Health Sciences
- Study site
- Mayo Clinic
- Registry record
- NCT06418204 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Lung cancer studies recruiting in Rochester
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Mayo Clinic Rochester
- Registry record
- NCT07277413 · updated
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Mayo Clinic in Rochester, Minnesota
- Registry record
- NCT07063745 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT04267848 · updated
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT04665739 · updated
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic - Rochester ( Site 0073)
- Registry record
- NCT06312137 · updated
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07291037 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Prostate cancer studies recruiting in Rochester
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT03866382 · updated
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- No phase
- Ages 18 and older
- Male participants
- Sponsor
- Axonics, Inc.
- Study site
- Mayo Clinic
- Registry record
- NCT06511141 · updated
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Mayo Clinic
- Registry record
- NCT03972657 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Melanoma studies recruiting in Rochester
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT05136196 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Rochester, MN on ClinicalTrials.gov.
Lymphoma studies recruiting in Rochester
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06724237 · updated
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT04840602 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT05675410 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06337318 · updated
Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06386315 · updated
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Mayo Clinic Rochester
- Registry record
- NCT05091424 · updated
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Mayo Clinic - Rochester
- Registry record
- NCT06091865 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Rochester, MN on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Rochester
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Mayo Clinical Rochester
- Registry record
- NCT07644559 · updated
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Mayo Clinic Rochester
- Registry record
- NCT07621718 · updated
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Mayo Clinic Rochester
- Registry record
- NCT07805954 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Ask about studies near Rochester
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections